Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Non-canonical AR activity facilitates endocrine resistance in breast cancer.

Chia K, Milioli H, Portman N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE, Lim E.

Endocr Relat Cancer. 2019 Feb 1;26(2):251-264. doi: 10.1530/ERC-18-0333.

PMID:
30557851
2.

Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response.

Shafi AA, Schiewer MJ, de Leeuw R, Dylgjeri E, McCue PA, Shah N, Gomella LG, Lallas CD, Trabulsi EJ, Centenera MM, Hickey TE, Butler LM, Raj G, Tilley WD, Cukierman E, Knudsen KE.

Eur Urol Oncol. 2018 Sep;1(4):325-337. doi: 10.1016/j.euo.2018.04.019. Epub 2018 Jun 6.

3.

Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b.

Snell CE, Gough M, Liu C, Middleton K, Pyke C, Shannon C, Woodward N, Hickey TE, Armes JE, Tilley WD.

Br J Cancer. 2018 Nov;119(11):1316-1325. doi: 10.1038/s41416-018-0331-3. Epub 2018 Nov 9.

PMID:
30410061
4.

A patient-derived explant (PDE) model of hormone-dependent cancer.

Centenera MM, Hickey TE, Jindal S, Ryan NK, Ravindranathan P, Mohammed H, Robinson JL, Schiewer MJ, Ma S, Kapur P, Sutherland PD, Hoffmann CE, Roehrborn CG, Gomella LG, Carroll JS, Birrell SN, Knudsen KE, Raj GV, Butler LM, Tilley WD.

Mol Oncol. 2018 Sep;12(9):1608-1622. doi: 10.1002/1878-0261.12354. Epub 2018 Aug 16.

5.

Androgen Receptor Signalling Promotes a Luminal Phenotype in Mammary Epithelial Cells.

Tarulli GA, Laven-Law G, Shehata M, Walters KA, Denis IM, Rahman MM, Handelsman DJ, Dean NR, Tilley WD, Hickey TE.

J Mammary Gland Biol Neoplasia. 2019 Mar;24(1):99-108. doi: 10.1007/s10911-018-9406-2. Epub 2018 Aug 12.

PMID:
30099649
6.

The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome.

Ricciardelli C, Bianco-Miotto T, Jindal S, Butler LM, Leung S, McNeil CM, O'Toole SA, Ebrahimie E, Millar EKA, Sakko AJ, Ruiz AI, Vowler SL, Huntsman DG, Birrell SN, Sutherland RL, Palmieri C, Hickey TE, Tilley WD.

Clin Cancer Res. 2018 May 15;24(10):2328-2341. doi: 10.1158/1078-0432.CCR-17-1199. Epub 2018 Mar 7.

7.

Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer.

Paltoglou S, Das R, Townley SL, Hickey TE, Tarulli GA, Coutinho I, Fernandes R, Hanson AR, Denis I, Carroll JS, Dehm SM, Raj GV, Plymate SR, Tilley WD, Selth LA.

Cancer Res. 2017 Jul 1;77(13):3417-3430. doi: 10.1158/0008-5472.CAN-16-1616. Epub 2017 May 4.

8.

Deciphering the divergent roles of progestogens in breast cancer.

Carroll JS, Hickey TE, Tarulli GA, Williams M, Tilley WD.

Nat Rev Cancer. 2017 Jan;17(1):54-64. doi: 10.1038/nrc.2016.116. Epub 2016 Nov 25. Review.

PMID:
27885264
9.

Pushing estrogen receptor around in breast cancer.

Lim E, Tarulli G, Portman N, Hickey TE, Tilley WD, Palmieri C.

Endocr Relat Cancer. 2016 Dec;23(12):T227-T241. Epub 2016 Oct 11. Review.

PMID:
27729416
10.

Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.

Hu DG, Selth LA, Tarulli GA, Meech R, Wijayakumara D, Chanawong A, Russell R, Caldas C, Robinson JL, Carroll JS, Tilley WD, Mackenzie PI, Hickey TE.

Cancer Res. 2016 Oct 1;76(19):5881-5893. Epub 2016 Aug 5.

11.

Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.

Singhal H, Greene ME, Tarulli G, Zarnke AL, Bourgo RJ, Laine M, Chang YF, Ma S, Dembo AG, Raj GV, Hickey TE, Tilley WD, Greene GL.

Sci Adv. 2016 Jun 24;2(6):e1501924. doi: 10.1126/sciadv.1501924. eCollection 2016 Jun.

12.

Small Glutamine-Rich Tetratricopeptide Repeat-Containing Protein Alpha (SGTA) Ablation Limits Offspring Viability and Growth in Mice.

Philp LK, Day TK, Butler MS, Laven-Law G, Jindal S, Hickey TE, Scher HI, Butler LM, Tilley WD.

Sci Rep. 2016 Jun 30;6:28950. doi: 10.1038/srep28950.

13.

Regulators of genetic risk of breast cancer identified by integrative network analysis.

Castro MA, de Santiago I, Campbell TM, Vaughn C, Hickey TE, Ross E, Tilley WD, Markowetz F, Ponder BA, Meyer KB.

Nat Genet. 2016 Jan;48(1):12-21. doi: 10.1038/ng.3458. Epub 2015 Nov 30.

14.

Expression of androgen receptor splice variants in clinical breast cancers.

Hickey TE, Irvine CM, Dvinge H, Tarulli GA, Hanson AR, Ryan NK, Pickering MA, Birrell SN, Hu DG, Mackenzie PI, Russell R, Caldas C, Raj GV, Dehm SM, Plymate SR, Bradley RK, Tilley WD, Selth LA.

Oncotarget. 2015 Dec 29;6(42):44728-44. doi: 10.18632/oncotarget.6296.

15.

Hormone-sensing mammary epithelial progenitors: emerging identity and hormonal regulation.

Tarulli GA, Laven-Law G, Shakya R, Tilley WD, Hickey TE.

J Mammary Gland Biol Neoplasia. 2015 Jun;20(1-2):75-91. doi: 10.1007/s10911-015-9344-1. Epub 2015 Sep 21. Review.

PMID:
26390871
16.

Corrigendum: Progesterone receptor modulates ERα action in breast cancer.

Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D'Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS.

Nature. 2015 Oct 1;526(7571):144. doi: 10.1038/nature14959. Epub 2015 Aug 5. No abstract available.

PMID:
26245370
17.

Progesterone receptor modulates ERα action in breast cancer.

Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D'Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS.

Nature. 2015 Jul 16;523(7560):313-7. doi: 10.1038/nature14583. Epub 2015 Jul 8. Erratum in: Nature. 2015 Oct 1;526(7571):144. Serandour, Aurelien A A[Corrected to Serandour, Aurelien A].

18.

Expression and localisation of c-kit and KITL in the adult human ovary.

Tuck AR, Robker RL, Norman RJ, Tilley WD, Hickey TE.

J Ovarian Res. 2015 May 26;8:31. doi: 10.1186/s13048-015-0159-x.

19.

Bringing androgens up a NOTCH in breast cancer.

Tarulli GA, Butler LM, Tilley WD, Hickey TE.

Endocr Relat Cancer. 2014 Aug;21(4):T183-202. doi: 10.1530/ERC-14-0248. Epub 2014 Jul 7. Review.

PMID:
25001242
20.

Mouse GDF9 decreases KITL gene expression in human granulosa cells.

Tuck AR, Mottershead DG, Fernandes HA, Norman RJ, Tilley WD, Robker RL, Hickey TE.

Endocrine. 2015 Mar;48(2):686-95. doi: 10.1007/s12020-014-0335-6. Epub 2014 Jul 2.

PMID:
24985063
21.

Complexities of androgen receptor signalling in breast cancer.

McNamara KM, Moore NL, Hickey TE, Sasano H, Tilley WD.

Endocr Relat Cancer. 2014 Aug;21(4):T161-81. doi: 10.1530/ERC-14-0243. Epub 2014 Jun 20. Review.

PMID:
24951107
22.

Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues.

Hu DG, Hickey TE, Irvine C, Wijayakumara DD, Lu L, Tilley WD, Selth LA, Mackenzie PI.

Horm Cancer. 2014 Apr;5(2):61-71. doi: 10.1007/s12672-014-0171-4. Epub 2014 Feb 26.

PMID:
24570075
23.

Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.

Robinson JL, Hickey TE, Warren AY, Vowler SL, Carroll T, Lamb AD, Papoutsoglou N, Neal DE, Tilley WD, Carroll JS.

Oncogene. 2014 Dec 11;33(50):5666-74. doi: 10.1038/onc.2013.508. Epub 2013 Dec 2.

24.

SGTA: a new player in the molecular co-chaperone game.

Philp LK, Butler MS, Hickey TE, Butler LM, Tilley WD, Day TK.

Horm Cancer. 2013 Dec;4(6):343-57. doi: 10.1007/s12672-013-0151-0. Epub 2013 Jul 2. Review.

PMID:
23818240
25.

Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo.

Ochnik AM, Moore NL, Jankovic-Karasoulos T, Bianco-Miotto T, Ryan NK, Thomas MR, Birrell SN, Butler LM, Tilley WD, Hickey TE.

Menopause. 2014 Jan;21(1):79-88. doi: 10.1097/GME.0b013e3182936ef4.

PMID:
23715406
26.

Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.

Butler MS, Ricciardelli C, Tilley WD, Hickey TE.

Horm Cancer. 2013 Jun;4(3):154-64. doi: 10.1007/s12672-013-0135-0. Epub 2013 Feb 27.

PMID:
23443946
27.

Small glutamine-rich tetratricopeptide repeat-containing protein alpha is present in human ovaries but may not be differentially expressed in relation to polycystic ovary syndrome.

Butler MS, Yang X, Ricciardelli C, Liang X, Norman RJ, Tilley WD, Hickey TE.

Fertil Steril. 2013 Jun;99(7):2076-83.e1. doi: 10.1016/j.fertnstert.2013.01.140. Epub 2013 Feb 20.

PMID:
23433514
28.

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.

Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES.

Cell Cycle. 2012 Jul 15;11(14):2756-61. doi: 10.4161/cc.21195. Epub 2012 Jul 15.

29.

Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?

Hickey TE, Robinson JL, Carroll JS, Tilley WD.

Mol Endocrinol. 2012 Aug;26(8):1252-67. doi: 10.1210/me.2012-1107. Epub 2012 Jun 28. Review.

30.

An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity.

Moore NL, Buchanan G, Harris JM, Selth LA, Bianco-Miotto T, Hanson AR, Birrell SN, Butler LM, Hickey TE, Tilley WD.

Endocr Relat Cancer. 2012 Jul 22;19(4):599-613. doi: 10.1530/ERC-12-0065. Print 2012 Aug.

PMID:
22719059
31.

Assessment of androgen concentration in women: liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results.

Janse F, Eijkemans MJ, Goverde AJ, Lentjes EG, Hoek A, Lambalk CB, Hickey TE, Fauser BC, Norman RJ.

Eur J Endocrinol. 2011 Dec;165(6):925-33. doi: 10.1530/EJE-11-0482. Epub 2011 Oct 3.

PMID:
21969522
32.

Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells.

Moore NL, Hickey TE, Butler LM, Tilley WD.

Mol Cell Endocrinol. 2012 Jun 24;357(1-2):60-70. doi: 10.1016/j.mce.2011.09.019. Epub 2011 Sep 16. Review.

PMID:
21945474
33.

FOXA1: master of steroid receptor function in cancer.

Augello MA, Hickey TE, Knudsen KE.

EMBO J. 2011 Sep 20;30(19):3885-94. doi: 10.1038/emboj.2011.340. Review.

34.

Identification of perilipin-2 as a lipid droplet protein regulated in oocytes during maturation.

Yang X, Dunning KR, Wu LL, Hickey TE, Norman RJ, Russell DL, Liang X, Robker RL.

Reprod Fertil Dev. 2010;22(8):1262-71. doi: 10.1071/RD10091.

PMID:
20883652
35.

Biomarkers: Polycystic ovary syndrome: steroid assessment for diagnosis.

Hickey TE, Norman RJ.

Nat Rev Endocrinol. 2010 Jun;6(6):305-7. doi: 10.1038/nrendo.2010.68. No abstract available.

PMID:
20502465
36.

Differential effects of Co(III), Ni(II), and Ru(III) amine complexes on Sindbis virus.

Andrew Knight D, Hickey TE, Bongard JE, Thach DC, Yngard R, Chang EL.

J Inorg Biochem. 2010 May;104(5):592-8. doi: 10.1016/j.jinorgbio.2010.01.012. Epub 2010 Feb 6.

PMID:
20189656
37.

Genetic and gene expression analyses of the polycystic ovary syndrome candidate gene fibrillin-3 and other fibrillin family members in human ovaries.

Prodoehl MJ, Hatzirodos N, Irving-Rodgers HF, Zhao ZZ, Painter JN, Hickey TE, Gibson MA, Rainey WE, Carr BR, Mason HD, Norman RJ, Montgomery GW, Rodgers RJ.

Mol Hum Reprod. 2009 Dec;15(12):829-41. doi: 10.1093/molehr/gap072. Epub 2009 Aug 19.

38.

Antiviral properties of cobalt(III)-complexes.

Delehanty JB, Bongard JE, Thach DC, Knight DA, Hickey TE, Chang EL.

Bioorg Med Chem. 2008 Jan 15;16(2):830-7. Epub 2007 Oct 13.

PMID:
17967542
39.

Binding and neutralization of lipopolysaccharides by plant proanthocyanidins.

Delehanty JB, Johnson BJ, Hickey TE, Pons T, Ligler FS.

J Nat Prod. 2007 Nov;70(11):1718-24. Epub 2007 Oct 20.

PMID:
17949054
40.

Polycystic ovary syndrome.

Norman RJ, Dewailly D, Legro RS, Hickey TE.

Lancet. 2007 Aug 25;370(9588):685-97. Review.

PMID:
17720020
41.

Heterogeneity of a Campylobacter jejuni protein that is secreted through the flagellar filament.

Poly F, Ewing C, Goon S, Hickey TE, Rockabrand D, Majam G, Lee L, Phan J, Savarino NJ, Guerry P.

Infect Immun. 2007 Aug;75(8):3859-67. Epub 2007 May 21.

42.

Molecular basis of oocyte-paracrine signalling that promotes granulosa cell proliferation.

Gilchrist RB, Ritter LJ, Myllymaa S, Kaivo-Oja N, Dragovic RA, Hickey TE, Ritvos O, Mottershead DG.

J Cell Sci. 2006 Sep 15;119(Pt 18):3811-21. Epub 2006 Aug 22.

43.

Epigenetic modification of the X chromosome influences susceptibility to polycystic ovary syndrome.

Hickey TE, Legro RS, Norman RJ.

J Clin Endocrinol Metab. 2006 Jul;91(7):2789-91. Epub 2006 Apr 24.

PMID:
16636126
45.

Androgens augment the mitogenic effects of oocyte-secreted factors and growth differentiation factor 9 on porcine granulosa cells.

Hickey TE, Marrocco DL, Amato F, Ritter LJ, Norman RJ, Gilchrist RB, Armstrong DT.

Biol Reprod. 2005 Oct;73(4):825-32. Epub 2005 Jun 22.

PMID:
15972887
47.

Interactions between androgen and growth factors in granulosa cell subtypes of porcine antral follicles.

Hickey TE, Marrocco DL, Gilchrist RB, Norman RJ, Armstrong DT.

Biol Reprod. 2004 Jul;71(1):45-52. Epub 2004 Feb 18.

PMID:
14973257
48.

DNA sequence and mutational analyses of the pVir plasmid of Campylobacter jejuni 81-176.

Bacon DJ, Alm RA, Hu L, Hickey TE, Ewing CP, Batchelor RA, Trust TJ, Guerry P.

Infect Immun. 2002 Nov;70(11):6242-50.

49.

Phase variation of Campylobacter jejuni 81-176 lipooligosaccharide affects ganglioside mimicry and invasiveness in vitro.

Guerry P, Szymanski CM, Prendergast MM, Hickey TE, Ewing CP, Pattarini DL, Moran AP.

Infect Immun. 2002 Feb;70(2):787-93.

50.

Sialylation of lipooligosaccharide cores affects immunogenicity and serum resistance of Campylobacter jejuni.

Guerry P, Ewing CP, Hickey TE, Prendergast MM, Moran AP.

Infect Immun. 2000 Dec;68(12):6656-62.

Supplemental Content

Loading ...
Support Center